Maddi Hebebrand, MC, Associate Editor

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.

Explore how synthetic data revolutionizes CSU research, enabling smaller sample sizes and enhancing trial efficiency and inclusivity.

Explore innovative acne therapies, including bimekizumab, offering hope for treatment-resistant acne conglobata and improved patient outcomes.

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

The FDA warned Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore innovative nonsteroidal treatments for atopic dermatitis, as experts discuss personalized care strategies to enhance patient quality of life.

Vitiligo significantly influences patients' quality of life, affecting major life decisions and increasing perceived stigma.

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with the recent approval of delgocitinib for adults with moderate to severe CHE.

Explore the complexities of chronic hand eczema, its impact on quality of life, and emerging treatment options in this insightful review.

BioMendics initiates TAMES-02 trial for TolaSure, a groundbreaking therapy targeting the root cause of Epidermolysis Bullosa Simplex, offering new hope.

The drug’s approval in August 2025 follows robust efficacy and safety results from the DELTA 1, 2, and 3 clinical trials.

Patients receiving BoNT-A plus topical cream reported greater satisfaction and better skin lightness than with cream alone.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the complexities of medication sampling, balancing patient access with ethical and safety concerns in clinical practice.

Parents advocate for children with chronic skin conditions, highlighting school challenges and the need for better support in pediatric dermatology.

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.